Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02335060 · ClinicalTrials.gov registry record · Early Phase 1
N-acetylcysteine Effects on Tetrahydrocannabinol
A Early Phase 1 study, sponsored by Yale University.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 5
- Enrollment target
NCT02335060: Clinical Trial Early Phase 1 study, sponsored by Yale University.
NCT02335060 is a Early Phase 1 study that was terminated before completion, run by Yale University. The registered enrollment target is 5 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (91% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02335060, a Early Phase 1 study, was terminated before completion, sponsored by Yale University.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
The overall purpose of this study is to examine the effect of N-acetylcysteine (NAC) on the acute effects of Delta-9-tetrahydrocannabinol (THC). This will be tested by pretreating healthy individuals with NAC and then assessing their responses to THC.
Primary Outcome
Positive, negative, and general symptoms will be assessed using the positive, negative, and general symptom subscales of the PANSS
Interventions
- DRUG Placebo
- DRUG N-acetylcysteine
- DRUG Delta-9-THC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2014-05-02 |
| Est. Completion | 2014-09-16 |
| Phase | Early Phase 1 |
Why NCT02335060 stopped before completion
NCT02335060 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (91% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02335060 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02335060 about?
NCT02335060 is a clinical study titled "N-acetylcysteine Effects on Tetrahydrocannabinol". The overall purpose of this study is to examine the effect of N-acetylcysteine (NAC) on the acute effects of Delta-9-tetrahydrocannabinol (THC). This will be tested by pretreating healthy individuals with NAC and then assessing their responses to THC.
What is the current status of trial NCT02335060?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 5 participants. The study started on 2014-05-02. Estimated completion is 2014-09-16.
What interventions are being tested in trial NCT02335060?
The interventions under investigation include: Placebo (DRUG), N-acetylcysteine (DRUG), Delta-9-THC (DRUG).
Who is sponsoring clinical trial NCT02335060?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02335060's enrollment target sits among peer trials
5 1887th of 2000 higher than 80 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI